bluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK Capital

Bluebird bio signed an agreement to be acquired by Carlyle and SK Capital. The original offer was $3 per share plus a contingent $6.84 per-share payment linked to a sales milestone. These were the February 2025 terms; the May amendment and June completion are recorded separately.